BusinessA New Study Published in The Annals of Thoracic Surgery: Daxor’s BVA-100 Device Reveals Unexpected Blood Loss of 38% in Cardiac Surgical Patients Not Detected by Common Test in UseBy Nasdaq OMXApr 19, 2018, 1:01 PM UTC
BusinessDaxor to Present at The MicroCap Conference on April 9th and 10th in New York City at the Essex HouseBy Nasdaq OMXApr 5, 2018, 1:01 PM UTC
BusinessDaxor Corporation Announces Positive New Critical Care Research Highlighting Benefit from BVA Use; Daxor Corporation to Exhibit at the American College of Cardiology 2018 Annual Meeting (NYSE MKT LLC: DXR)By Nasdaq OMXMar 9, 2018, 4:54 PM UTC
BusinessDaxor Corporation Announces Rise in Kit Sales, New Device Sale, and Filing of Form N-CSR for 2017 (NYSE MKT LLC: DXR)By Nasdaq OMXMar 8, 2018, 5:56 PM UTC
